Welcome to our dedicated page for Mineralys Therapeutics SEC filings (Ticker: MLYS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Mineralys Therapeutics, Inc. filings document the public-company disclosures of a biopharmaceutical issuer developing lorundrostat for hypertension and related comorbidities driven by dysregulated aldosterone. Form 8-K reports cover quarterly and annual financial results, corporate updates, Regulation FD disclosures, FDA acceptance of the lorundrostat New Drug Application, and clinical results from the Explore-OSA exploratory trial.
The filing record also includes proxy materials for annual meeting voting and stockholder procedures, along with material-event disclosures for capital-structure matters. These include common stock arrangements under an ATM Equity Offering Sales Agreement, registration-statement references, material agreements, and shareholder voting matters.
Mineralys Therapeutics, Inc. insider Jon Congleton filed to sell common stock under Rule 144. The filing covers a proposed sale of 10,700 shares of common stock, to be executed through Merrill Lynch on 07/13/2026 on Nasdaq, with an aggregate market value of $291,441.17. These shares relate to restricted stock units that vested on 07/10/2026 and were granted under the issuer’s equity compensation plan. Over the prior three months, Congleton sold 15,730 shares for $421,979.55 on 04/13/2026 and 75,000 shares for $1,960,601.58 on 06/30/2026.
Mineralys Therapeutics, Inc. has a planned sale of common stock by an affiliate through Merrill Lynch on NASDAQ, related to an exercise of employee stock options using a broker-assisted cashless exercise on 07/13/2026. In the prior three months, David Rodman reported multiple open-market sales of the company’s common stock on various dates in April, May, June, and July 2026, with individual transactions ranging from a few hundred to over 14,000 shares and aggregate dollar values per trade from tens of thousands to over $400,000.
Mineralys Therapeutics, Inc. Chief Medical Officer David Malcom Rodman exercised stock options and sold common shares in a coordinated transaction. He exercised 2,171 stock options at $16.00 per share, then sold 2,171 common shares at $30.30 per share under a Rule 10b5-1 trading plan adopted on October 6, 2025. Following these transactions, he holds 57,733 common shares, including 638 shares from the 2023 Employee Stock Purchase Plan, and retains 15,194 stock options exercisable at $16.00 per share expiring on February 9, 2033.
Mineralys Therapeutics, Inc. reported a Form 144 disclosing a broker-assisted cashless exercise and related sales activity. The filing shows an exercise of 2,171 shares on 07/09/2026 via broker-assisted cashless exercise and lists multiple sales by David Rodman between 04/09/2026 and 06/17/2026, with individual transactions ranging from 416 to 14,056 shares and corresponding gross proceeds recorded per trade.
Mineralys Therapeutics, Inc. director and Chief Executive Officer Jon Congleton reported selling a total of 75,000 shares of common stock in open-market transactions on June 30, 2026. The filing shows two sales: 58,000 shares at a weighted-average price of $25.9432 per share and 17,000 shares at a weighted-average price of $26.8174 per share.
According to the footnotes, these transactions were executed under a Rule 10b5-1 trading plan adopted on December 30, 2025, and each reported price reflects multiple trades within disclosed price ranges. The Form 4 indicates that Congleton continues to hold a substantial direct stake in Mineralys common stock following these sales.
Mineralys Therapeutics Chief Commercial Officer Eric Warren exercised stock options and sold shares in a planned transaction. He exercised options for 104,124 shares of common stock at $13.24 per share and sold 104,124 shares at a weighted-average price of $25.8953 per share.
These trades were carried out under a Rule 10b5-1 stock selling plan adopted on March 27, 2026, indicating they were pre-scheduled. Following the transactions, Warren directly owns 38,400 shares of Mineralys common stock.
Mineralys Therapeutics reported proposed sales of Common Stock by an affiliate under a Form 144 notice. The filing lists prior transfers of 75,000 shares on 03/31/2026 for $1,970,520.69 and 15,730 shares on 04/13/2026 for $421,979.55. The excerpt also lists scheduled vesting of restricted share unit awards on 07/10/2024, 10/10/2024, and 01/10/2025 for 24,619, 35,954, and 14,427 shares respectively.
Mineralys Therapeutics reports a Form 144 notice to sell 104,124 shares of Common Stock.
The filing lists a broker-assisted cashless exercise tied to the exercise of employee stock options on 06/26/2026, shows proceeds of $2,696,321.98, and records 82,498,101 shares outstanding as of 06/26/2026. The broker named is Merrill Lynch.
Mineralys Therapeutics Chief Medical Officer David Malcom Rodman reported a mix of option exercises and share sales in mid-June. On June 15 and June 17, he sold a total of 14,474 shares of common stock in open-market transactions at weighted-average prices around $23.81 and $25.00.
To support these sales, he exercised stock options covering 8,126 shares at exercise prices of $10.20, $14.25 and $15.44. After the transactions, he directly holds 57,095 shares of common stock. The filing notes that the trades were executed under a pre-arranged Rule 10b5-1 trading plan adopted on October 6, 2025.
Mineralys Therapeutics director Daphne Karydas exercised stock options for 3,000 shares of common stock at $12.02 per share and sold 3,000 shares at $25.00 per share. After these transactions, she holds 6,200 shares directly. The trades were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 30, 2025.